Literature DB >> 10655553

Functional analysis of novel mutations in y(+)LAT-1 amino acid transporter gene causing lysinuric protein intolerance (LPI).

J Mykkänen1, D Torrents, M Pineda, M Camps, M E Yoldi, N Horelli-Kuitunen, K Huoponen, M Heinonen, J Oksanen, O Simell, M L Savontaus, A Zorzano, M Palacín, P Aula.   

Abstract

Lysinuric protein intolerance (LPI; MIM 222700) is an autosomal recessive disorder characterized by defective transport of the cationic amino acids lysine, arginine and ornithine at the basolateral membrane of the polar epithelial cells in the intestine and renal tubules, and by hyperammonemia after high-protein meals. LPI is caused by mutations in the SLC7A7 (solute carrier family 7, member 7) gene encoding y(+)LAT-1 (y(+)L amino acid transporter-1), which co-induces together with 4F2 heavy chain (4F2hc) system y(+)L in Xenopus oocytes. All Finnish LPI patients share the same founder mutation 1181-2A-->T (LPI(Fin)) not found in LPI patients elsewhere. Mutation screening of 20 non-Finnish LPI patients revealed 10 novel mutations: four deletions, two missense mutations, two nonsense mutations, a splice site mutation and a tandem duplication. Five LPI mutations (L334R, G54V, 1291delCTTT, 1548delC and LPI(Fin)) were studied functionally. All mutant proteins failed to co-induce amino acid transport activity when expressed with 4F2hc in Xenopus oocytes. Immunostaining experiments revealed that frameshift mutants 1291delCTTT, 1548delC and LPI(Fin)remained intracellular on expression with 4F2hc. In contrast, the missense mutants L334R and G54V reached the oocyte plasma membrane when co-expressed with 4F2hc, demonstrating that they are transport-inactivating mutations. This finding, together with the strong degree of conservation among all members of this family of amino acid transporters, indicates that residues L334 and G54 play a crucial role in the function of the y(+)LAT-1 transporter.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10655553     DOI: 10.1093/hmg/9.3.431

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  15 in total

Review 1.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

2.  The light subunit of system b(o,+) is fully functional in the absence of the heavy subunit.

Authors:  Núria Reig; Josep Chillarón; Paola Bartoccioni; Esperanza Fernández; Annie Bendahan; Antonio Zorzano; Baruch Kanner; Manuel Palacín; Joan Bertran
Journal:  EMBO J       Date:  2002-09-16       Impact factor: 11.598

Review 3.  CATs and HATs: the SLC7 family of amino acid transporters.

Authors:  François Verrey; Ellen I Closs; Carsten A Wagner; Manuel Palacin; Hitoshi Endou; Yoshikatsu Kanai
Journal:  Pflugers Arch       Date:  2003-06-11       Impact factor: 3.657

4.  Deleterious nonsynonymous single nucleotide polymorphisms in human solute carriers: the first comparison of three prediction methods.

Authors:  Da-Cheng Hao; Bing Xiao; Ying Xiang; Xue-Wei Dong; Pei-Gen Xiao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-05-04       Impact factor: 2.441

5.  A global Slc7a7 knockout mouse model demonstrates characteristic phenotypes of human lysinuric protein intolerance.

Authors:  Bridget M Stroup; Ronit Marom; Xiaohui Li; Chih-Wei Hsu; Cheng-Yen Chang; Luan D Truong; Brian Dawson; Ingo Grafe; Yuqing Chen; Ming-Ming Jiang; Denise Lanza; Jennie Rose Green; Qin Sun; J P Barrish; Safa Ani; Audrey E Christiansen; John R Seavitt; Mary E Dickinson; Farrah Kheradmand; Jason D Heaney; Brendan Lee; Lindsay C Burrage
Journal:  Hum Mol Genet       Date:  2020-08-03       Impact factor: 6.150

6.  Vascular endothelial dysfunction resulting from L-arginine deficiency in a patient with lysinuric protein intolerance.

Authors:  Y Kamada; H Nagaretani; S Tamura; T Ohama; T Maruyama; H Hiraoka; S Yamashita; A Yamada; S Kiso; Y Inui; N Ito; Y Kayanoki; S Kawata; Y Matsuzawa
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

Review 7.  Overview of symptoms and treatment for lysinuric protein intolerance.

Authors:  Atsuko Noguchi; Tsutomu Takahashi
Journal:  J Hum Genet       Date:  2019-06-18       Impact factor: 3.172

Review 8.  Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology.

Authors:  Stephen J Fairweather; Nishank Shah; Stefan Brӧer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Novel SLC7A7 large rearrangements in lysinuric protein intolerance patients involving the same AluY repeat.

Authors:  Mariona Font-Llitjós; Benjamín Rodríguez-Santiago; Meritxell Espino; Ruth Sillué; Sandra Mañas; Laia Gómez; Luis A Pérez-Jurado; Manuel Palacín; Virginia Nunes
Journal:  Eur J Hum Genet       Date:  2008-08-20       Impact factor: 4.246

10.  The first Korean case of lysinuric protein intolerance: presented with short stature and increased somnolence.

Authors:  Jung Min Ko; Choong Ho Shin; Sei Won Yang; Moon Woo Seong; Sung Sup Park; Junghan Song
Journal:  J Korean Med Sci       Date:  2012-07-25       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.